Reversal of apoptosis:an in vivo mechanism for cytoprotection and mutagenesis

细胞凋亡的逆转:细胞保护和诱变的体内机制

基本信息

项目摘要

DESCRIPTION (provided by applicant): Apoptosis plays essential roles in development and homeostasis in multicellular organisms by sculpting tissues, deleting unwanted structures, and eliminating abnormal, injured or dangerous cells. In addition, targeting apoptotic pathways is an important strategy for treatment of intractable diseases such as cancer, whereas limiting apoptosis may be beneficial for treating ischemic injury and degenerative disorders. Although loss- or gain-of-function of apoptotic regulators can artificially allow cells to survive beyond normal checkpoints, apoptosis is generally assumed to be an intrinsically irreversible process. However, we recently discovered a natural reversibility of late-stage apoptosis in human and mouse cells. Dying cells can reverse apoptosis and survive, despite having passed through checkpoints previously believed to be the point of no return, including caspase-3 activation and DNA damage. Simply washing away apoptotic inducers is sufficient to allow the majority of dying cells to survive and most hallmarks of apoptosis to vanish, indicating that reversal of apoptosis is an endogenous cellular mechanism. Notably, while most cells recover completely, a small fraction of cells that reverse apoptosis retain genetic alterations and undergo oncogenic transformation at a higher frequency than control cells. We propose that reversal of apoptosis may be a physiological mechanism that can serve several beneficial functions. Arrest of apoptosis at the execution stage could in principle promote survival of cells, such as neurons and heart muscle cells, which are difficult to replace. Alternatively or in addition, this recovery process, which we have named anastasis (Greek for rising to life), could promote genetic and phenotypic diversity in response to environmental or physiological stresses that initiate apoptosis. A negative side effect of this otherwise beneficial process is oncogenic transformation. We have developed and tested a biosensor to detect cells that have undergone anastasis in vivo in Drosophila melanogaster. In specific aim 1 we will test the hypothesis that anastasis functions to salvage cells that are difficult to replace, thus limiting permanent tissue damage following transient insults. We also propose to develop a similar biosensor for use in mammalian cells. In specific aim 2 we propose to initiate studies of the molecular mechanisms controlling anastasis. The proposed work has the potential to lead to a new understanding of and treatments for degenerative diseases and cancer.
描述(由申请人提供):凋亡通过雕刻组织,删除不需要的结构并消除异常,受伤或危险细胞,在多细胞生物中发育和稳态中起着重要作用。此外,靶向凋亡途径是治疗棘手疾病(例如癌症)的重要策略,而限制凋亡可能对治疗缺血性损伤和退化性疾病有益。尽管凋亡调节剂的丧失或功能损失可以人为地允许细胞在正常检查点上生存,但通常认为凋亡是一种本质上不可逆的过程。但是,我们最近发现了人和小鼠细胞中晚期凋亡的自然可逆性。垂死的细胞可以逆转凋亡并生存,尽管已经通过了以前认为是无回报的检查点,包括caspase-3激活和DNA损伤。只需清洗凋亡诱导剂就足以使大多数垂死的细胞生存,大多数凋亡的标志都消失了,这表明凋亡的逆转是一种内源性细胞机制。值得注意的是,尽管大多数细胞完全恢复,但逆转凋亡的一小部分细胞保留了遗传改变并在较高的频率下进行致癌细胞转化。我们认为凋亡的逆转可能是可以发挥多种有益功能的生理机制。在执行阶段的凋亡原则上可能会促进细胞的存活,例如神经元和心肌细胞,这些细胞难以替代。或者,此恢复 我们将其命名为Anastasis的过程(希腊语上升为生命),可以促进造成细胞凋亡的环境或生理压力的响应,以促进遗传和表型多样性。这个原本有益的过程的负面副作用是致癌转化。我们已经开发并测试了一个生物传感器,以检测在果蝇中经体体内吻合的细胞。在特定的目标1中,我们将测试以下假设:吻合曲与难以替代的挽救细胞的功能,从而限制了短暂损伤后的永久组织损伤。我们还建议开发类似的生物传感器,用于哺乳动物细胞。在特定目标2中,我们建议启动对控制吻合的分子机制的研究。拟议的工作有可能导致对退行性疾病和癌症的新理解和治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Denise J. Montell其他文献

Editorial: Special issue SCDB "Cell death and survival": Cell death and resilience in health and disease.
社论:SCDB 特刊“细胞死亡与生存”:健康和疾病中的细胞死亡与恢复力。
共 1 条
  • 1
前往

Denise J. Montell的其他基金

Mechanisms of stem cell preservation and lifespan extension in Drosophila
果蝇干细胞保存和寿命延长的机制
  • 批准号:
    9803243
    9803243
  • 财政年份:
    2019
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Mechanisms of stem cell preservation and lifespan extension in Drosophila
果蝇干细胞保存和寿命延长的机制
  • 批准号:
    10399509
    10399509
  • 财政年份:
    2019
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Mechanisms of stem cell preservation and lifespan extension in Drosophila
果蝇干细胞保存和寿命延长的机制
  • 批准号:
    10625313
    10625313
  • 财政年份:
    2019
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
2015 Directed Cell Migration Gordon Research Conference & Gordon Research Seminar
2015年定向细胞迁移戈登研究会议
  • 批准号:
    8837312
    8837312
  • 财政年份:
    2015
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Anastasis, a new mechanism driving cell survival and evolution
Anastasis,驱动细胞生存和进化的新机制
  • 批准号:
    8932673
    8932673
  • 财政年份:
    2014
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Anastasis, a new mechanism driving cell survival and evolution
Anastasis,驱动细胞生存和进化的新机制
  • 批准号:
    9099812
    9099812
  • 财政年份:
    2014
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Anastasis, a new mechanism driving cell survival and evolution
Anastasis,驱动细胞生存和进化的新机制
  • 批准号:
    8750779
    8750779
  • 财政年份:
    2014
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Reversal of apoptosis:an in vivo mechanism for cytoprotection and mutagenesis
细胞凋亡的逆转:细胞保护和诱变的体内机制
  • 批准号:
    8589289
    8589289
  • 财政年份:
    2013
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Regulation of Cell Migration in Development
发育过程中细胞迁移的调控
  • 批准号:
    7929984
    7929984
  • 财政年份:
    2009
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
DISCOVERY
发现
  • 批准号:
    7313396
    7313396
  • 财政年份:
    2006
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:

相似国自然基金

丁苯酞通过调节细胞异常自噬和凋亡来延缓脊髓性肌萎缩症动物模型脊髓运动神经元的丢失
  • 批准号:
    82360332
  • 批准年份:
    2023
  • 资助金额:
    31.00 万元
  • 项目类别:
    地区科学基金项目
利用可视可控hypocretin神经元凋亡的疾病模型进行发作性睡病发病机制研究
  • 批准号:
    81901346
  • 批准年份:
    2019
  • 资助金额:
    20.5 万元
  • 项目类别:
    青年科学基金项目
组织器官衰老致退行性演变多示踪剂全身动态PET显像研究
  • 批准号:
    91949121
  • 批准年份:
    2019
  • 资助金额:
    68.0 万元
  • 项目类别:
    重大研究计划
日粮AFB1在反刍动物肝脏中代谢激活和诱导肝细胞凋亡的分子机理研究
  • 批准号:
    31902187
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
阿司匹林丁香酚酯抗氧化应激致血管内皮细胞凋亡的分子机制
  • 批准号:
    31872518
  • 批准年份:
    2018
  • 资助金额:
    59.0 万元
  • 项目类别:
    面上项目

相似海外基金

Development of Potent and non-toxic rexinoids to prevent non-melanoma skin cancer
开发有效且无毒的类毒素来预防非黑色素瘤皮肤癌
  • 批准号:
    10562891
    10562891
  • 财政年份:
    2023
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities
HER1-3 和死亡受体蛋白折叠作为治疗漏洞
  • 批准号:
    10721930
    10721930
  • 财政年份:
    2023
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Dermal-Epidermal Junction Disruptors: Toxicodynamic Mechanisms
真皮-表皮连接干扰物:毒效机制
  • 批准号:
    10629516
    10629516
  • 财政年份:
    2023
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Health Effects of the Fluorinated Pollutants; PFAS on Enamel Development
氟化污染物对健康的影响;
  • 批准号:
    10697298
    10697298
  • 财政年份:
    2023
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别:
Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke
Kv2.1 靶向急性缺血性中风的一流神经保护疗法
  • 批准号:
    10598185
    10598185
  • 财政年份:
    2023
  • 资助金额:
    $ 18.8万
    $ 18.8万
  • 项目类别: